… activation with BRAF inhibitor monotherapy. In this review, we discuss existing clinical trial
data on BRAF and MEK inhibitors together and in combinations with other therapeutic agents. …

… -activated extracellular signal-regulated kinase (MEK), have been developed. … therapeutic
oncogenic target. Particular attention is paid to MEK inhibitors (MEKi) as promising therapeutic …

… Future combinations of MEK inhibitors with other cancer therapy options, currently … of MEK
inhibition in treating BRAF mutant melanoma. In addition, combination BRAF/MEK inhibitor …

… activities on MEK inhibitors in recent year (2015–present). … therapies for melanoma, and
in particular, metastatic melanoma. Drugs for use in such therapies include MEK inhibitors …

… inhibitor (vemurafenib and dabrafenib) resistance. We also review the advantages of dual
therapy, including the addition of an MEK inhibitor (… compared to BRAF inhibitor monotherapy. …

… Citation17 In a Phase I study of the MEK inhibitor trametinib in combination with the AKT
inhibitor afuresertib in patients with solid tumors and multiple myeloma, continuous daily dosing …

… side effect of these therapies using MEK inhibitors may enhance their … /MEK/ERK pathway
may be necessary for prescribing MEK inhibitors as part of their therapy, as MEK inhibitors are …

… Then, patients were randomly assigned to receive combination therapy with dabrafenib plus
… any RAF or MEK inhibitor. The rate of CR or PR with the combination therapy was 76%, as …

… /MEK inhibitors in the treatment of this disease. We describe the recent development of the
selective MEK inhibitor … and describe its place in the melanoma therapeutic armamentarium. …

… understanding of science and therapeutic use of the MEK inhibitors targeting the RAS/RAF/ …
When iodo group was put in place of 4OMe on the benzoate in 67, another magnitude …